Levodopa Improves Behavioral Deficits of Mice with Parkinson's Disease Symptoms via Curbing NLRP3 Inflammasome Activation and Enhancing Tyrosine Hydroxylase Levels in the Striatum and Substantia Nigra

Objective: Levodopa (L-DOPA) is the primary treatment for Parkinson’s disease (PD). Nevertheless, the underlying mechanism of its action is not entirely learned. This study aims to probe the action of L-DOPA on NLR pyrin domain containing 3 (NLRP3) inflammasome activation and tyrosine hydroxylase (T...

Full description

Bibliographic Details
Main Authors: Xi Chen, Zhao Wang, Weihua Yang, Yuejun Fu
Format: Article
Language:English
Published: IMR Press 2024-01-01
Series:Journal of Integrative Neuroscience
Subjects:
Online Access:https://www.imrpress.com/journal/JIN/23/1/10.31083/j.jin2301002